GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 225 Note 54 : Event occurring after balance sheet date The Board of Directors has recommended a Dividend of ` 30 per equity share of face value of ` 10 each for this year. (March 31, 2020: ` 40 per share) (Refer Note 49 (b)). Note 55: The spread of Covid-19 is having an unprecedented impact on people and economy. This has impacted our operations and results for the year ended March 31, 2021. The Group has considered the possible effects that may result from the pandemic relating to Covid-19 on the carrying amounts of trade receivables, tangible assets, intangible assets and investments. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Group, as at the date of approval of these financial statements has used internal and external sources of information. The impact assessment of Covid-19 is a continuing process given the uncertainities and the Group will continue to closely monitor the developments. Note 56: Previous year figures have been regrouped / reclassified wherever necessary. Note 57: Approval of financial statements The financial statements were approved for issue by the Board of Directors on May 18, 2021 In terms of our report attached For Deloitte Haskins & Sells LLP For and on behalf of the Board of Directors Chartered Accountants R. S. Karnad Chairperson DIN: 00008064 S. Venkatesh Managing Director DIN: 07263117 Rupen K. Bhatt P. Thakur CFO & Whole-time Director DIN: 07971789 Partner D. Sundaram Audit Committee Chairman DIN: 00016304 A. Nadkarni Company Secretary FCS 10460 Mumbai, May 18, 2021 Mumbai, May 18, 2021